<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="353">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02265250</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00037025</org_study_id>
    <nct_id>NCT02265250</nct_id>
  </id_info>
  <brief_title>Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment</brief_title>
  <official_title>Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular disease (CVD) remains the leading cause of death in the United States, and&#xD;
      improved CVD risk assessment is needed for personalized medicine. Atherosclerosis measures&#xD;
      including plaque volume and adverse plaque features have prognostic value. Novel techniques&#xD;
      have been developed for assessing carotid, coronary, and femoral atherosclerosis using&#xD;
      magnetic resonance imaging (MRI) methods that are rapid and reproducible, have improved&#xD;
      spatial resolution, and do not require contrast media, making atherosclerosis assessment in&#xD;
      multiple vascular beds feasible during a single MRI session. This pilot research will provide&#xD;
      preliminary data to develop an innovative global atherosclerosis measure including carotid,&#xD;
      coronary, and femoral vascular beds, for assessing cardiovascular risk and for monitoring&#xD;
      atherosclerosis response to therapy. 20 participants will be recruited in one year.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are up to 2 study visits in this study.&#xD;
&#xD;
      During the first visit, the investigators will obtain non-contrast MRI (carotid, coronary,&#xD;
      and femoral) in 20 subjects with known coronary atherosclerosis but varying degrees of CVD&#xD;
      risk.&#xD;
&#xD;
        1. 5 asymptomatic subjects with lower CVD risk (recent coronary artery calcium score [CACS]&#xD;
           10-299)&#xD;
&#xD;
        2. 5 asymptomatic subjects with higher CVD risk (CACS 300-1000)&#xD;
&#xD;
        3. 5 subjects with known coronary atherosclerosis and stable angina&#xD;
&#xD;
        4. 5 subjects with known atherosclerosis and recent acute myocardial infarction&#xD;
&#xD;
      The investigators will measure plaque volume and assess adverse plaque features (intra-plaque&#xD;
      hemorrhage, positive remodeling, lesion eccentricity) in the three vascular beds.&#xD;
&#xD;
      Eight of these subjects with evidence of large plaque burden by MRI will be asked to return&#xD;
      for a simultaneous positron emission tomography (PET)-MRI imaging with 18F-sodium fluoride&#xD;
      (18F-NaF) of their carotid, coronary, and femoral arteries, in which 18F-NaF uptake in plaque&#xD;
      will represent micro-calcifications, which is associated with high-risk plaque.&#xD;
&#xD;
      In all 20 subjects, the investigators will also measure the following biomarkers which have&#xD;
      been shown to be useful for CVD risk assessment of atherosclerosis: LDL, HDL, lipoprotein(a),&#xD;
      apolipoprotein B/A-1 ratio, hemoglobin A1c, adiponectin, and highly sensitive C-reactive&#xD;
      protein. The investigators will also calculate their estimated 10-year and lifetime&#xD;
      atherosclerotic CVD risk (American Heart Association), Framingham 10-year CVD risk, and&#xD;
      Reynolds 10-year CVD risk scores.&#xD;
&#xD;
      We aim to obtain the second scan within 3 months of the first visit; thus, the subjects will&#xD;
      participate in the study for approximately 3 months.&#xD;
&#xD;
      All the procedures are research-related. The research visit will take approximately 3 hours,&#xD;
      and there will be maximum two visits. There are no collaborations with other sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plaque Volume</measure>
    <time_frame>24 hours</time_frame>
    <description>Quantitative plaque measurement using MRI software (VesselMass)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse plaque features</measure>
    <time_frame>24 hours</time_frame>
    <description>Presence of positive remodeling, lesion eccentricity, and intraplaque hemorrhage of plaque, on MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>18F-NaF PET uptake</measure>
    <time_frame>3-6 months</time_frame>
    <description>Measured as maximum tissue/background ratio (TBR), to assess for high-risk plaque</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory biomarkers</measure>
    <time_frame>24 hours</time_frame>
    <description>Measured as levels of LDL-C, HDL-C, lipoprotein(a), ApoB/ApoA-1 ratio, hemoglobin A1c, plasma adiponectin, hsCRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical risk scores</measure>
    <time_frame>24 hours</time_frame>
    <description>Measured as (1) ACC/AHA 10-year and lifetime atherosclerotic CVD risk, (2) Framingham 10-year CVD risk, and (3) Reynolds Risk 10-year CVD risk</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Asymptomatic, CACS &lt;300</arm_group_label>
    <description>5 asymptomatic subjects with low CVD risk, defined as recent coronary artery calcium score (CACS) &lt;300&#xD;
Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic, CACS ≥300</arm_group_label>
    <description>5 asymptomatic subjects with increased CVD risk, defined as a recent coronary artery calcium score (CACS) ≥300&#xD;
Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stable angina</arm_group_label>
    <description>5 subjects with stable angina and evidence of coronary atherosclerosis based on a recent invasive or CT coronary angiogram&#xD;
Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recent acute MI</arm_group_label>
    <description>5 subjects with a recent acute myocardial infarction (within 1 month) and evidence of coronary atherosclerosis based on invasive or CT coronary angiogram&#xD;
Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Noncontrast T1- and T2-weighted 3.0 T MRI of the bilateral carotid, coronary, and superficial femoral arteries</description>
    <arm_group_label>Asymptomatic, CACS &lt;300</arm_group_label>
    <arm_group_label>Asymptomatic, CACS ≥300</arm_group_label>
    <arm_group_label>Recent acute MI</arm_group_label>
    <arm_group_label>Stable angina</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PET/MRI</intervention_name>
    <description>Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries</description>
    <arm_group_label>Asymptomatic, CACS ≥300</arm_group_label>
    <arm_group_label>Recent acute MI</arm_group_label>
    <arm_group_label>Stable angina</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory blood test</intervention_name>
    <description>Cardiovascular biomarkers</description>
    <arm_group_label>Asymptomatic, CACS &lt;300</arm_group_label>
    <arm_group_label>Asymptomatic, CACS ≥300</arm_group_label>
    <arm_group_label>Recent acute MI</arm_group_label>
    <arm_group_label>Stable angina</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      We will obtain fasting lipid and inflammatory biomarkers (LDL-C, HDL-C, lipoprotein(a),&#xD;
      ApoB/ApoA-1 ratio, hemoglobin A1c, plasma adiponectin, hsCRP).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        20 subjects with known coronary atherosclerosis but varying degrees of CVD risk&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women with evidence of coronary atherosclerosis based on a recent CACS 10-1000&#xD;
             or an invasive or CT coronary angiogram (within 6 weeks of recruitment)&#xD;
&#xD;
          2. No planned revascularization procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications to MRI&#xD;
&#xD;
          2. Pregnant and lactating women&#xD;
&#xD;
          3. Body mass index (BMI)&gt;40&#xD;
&#xD;
          4. Active smoking&#xD;
&#xD;
          5. Resting heart rate&gt;75 beats per minute&#xD;
&#xD;
          6. Arrhythmia&#xD;
&#xD;
          7. Prior carotid/coronary/peripheral revascularization&#xD;
&#xD;
          8. Life expectancy &lt;5 years&#xD;
&#xD;
          9. Allergy to animal dander&#xD;
&#xD;
         10. Severe asthma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Wei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noel Bairey Merz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denisse Barajas</last_name>
    <phone>310-423-9666</phone>
    <email>denisse.barajas@cshs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Mou, PhD</last_name>
      <phone>310-248-7669</phone>
      <email>ying.mou@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Sophie Yoo, MS</last_name>
      <phone>424-315-4306</phone>
      <email>Jihye.Yoo@cshs.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 3, 2014</study_first_submitted>
  <study_first_submitted_qc>October 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2014</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Janet Wei</investigator_full_name>
    <investigator_title>Co-Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>positron emission tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

